Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization

Infertility Clinical Trial

— Prestyje  

Official title:

A Multicentre, Open-label, Non-comparative Phase IIIb Study to Evaluate the Acceptability of GONAL-f® Prefilled Liquid Formulation Administered by Pen in an Outpatient Setting for Ovarian Stimulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01183143
• Other study ID #: IMP 25040
• Status: Completed
• Phase: Phase 3
• First received: August 16, 2010
• Last updated: April 5, 2018
• Start date: May 11, 2004
• Est. completion date: March 2, 2006

Study information

• Verified date: April 2018
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a prospective, open-label, non-comparative, Phase IIIb trial to assess the convenience, safety and efficacy of the new Gonal-F fbm [recombinant follicle stimulating hormone (r-FSH)] liquid formulation, in common setting for ovulation induction (OI) and also in in-vitro fertilization (IVF).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 215
• Est. completion date: March 2, 2006
• Est. primary completion date: March 2, 2006
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 43 Years

Eligibility

Inclusion Criteria:

• Female subjects aged between 18 and 43 years

• Ambulatory subjects

• Subjects who are willing to get pregnant and are infertile, that justifies ovarian stimulation treatment for mono-/pauci-follicular development (OI or IUI) or multiple follicular development for IVF/Intracytoplasmic Sperm Injection (ICSI) procedures

• Subjects who are able to communicate well with the investigator and to comply with the requirements of the entire study

• Subjects who have given written informed consent, prior to treatment

Exclusion Criteria:

• Subjects with enlarged ovaries or cysts unrelated to polycystic ovaries

• Subjects with extra-uterine pregnancy during the last 3 months

• Subjects with several endometriosis (Grade III & IV)

• Subjects with history of severe ovarian hyperstimulation syndrome

• Subjects with history of thromboembolic event

• Subjects with malformative uterine pathology that could disturb either implantation or pregnancy processes

• Subjects with premature menopause

• Subjects with gynecological bleeding of unknown origin

• Subjects with ovarian, uterine, or mammary cancer

• Subjects with tumors of the hypothalamus or the pituitary glands

• Subjects with history of serious allergy or atopic asthma disease

• Subjects with known allergic reaction against one of the Follicle Stimulating Hormone (FSH) and ingredients,

• Ongoing pregnant, or breast feeding subjects

• Subjects who have participated in a trial during the last 3 months

Related Conditions & MeSH terms

• In-Vitro Fertilization
• Infertility
• Ovulation Induction

Intervention

Drug:
• GONAL-f®
GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.

Locations

Country	Name	City	State
Germany	Please Contact the Merck KGaA Communication Center	Darmstadt

Sponsors (1)

Lead Sponsor	Collaborator
Merck KGaA

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP)	Number of subjects who self-administered the IMP were presented in this outcome measure.	Up to 1 year
Secondary	Global Evaluation of the GONAL-f® Prefilled Pen by the Investigator	Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction.	Up to 1 year
Secondary	Evaluation of the Information Given to the Subjects on the Pen's Utilization	Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory.	Up to 1 year
Secondary	Duration of Ovarian Stimulation With GONAL-f®	Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment.	Up to 1 year
Secondary	Mean Number of Embryos Transferred		End of Stimulation period (up to a maximum 26 days)
Secondary	Total and Average Daily Dose of GONAL-f®		Up to 26 days
Secondary	Pregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI)	Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation.	Up to 20 Weeks of Gestation
Secondary	Number of Subjects With Live Birth	Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported.	End of Gestation period, assessed up to a maximum of 1 year
Secondary	Number of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator	Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma.	Up to 1 year
Secondary	Number of Subjects With at Least 1 Adverse Event	An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered.	Up to 1 year
Secondary	Number of Subjects Taking at Least 1 Concomitant Treatment		Up to 1 year